JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
218,42 USD
arrow_downward
−1,81%(−4,03) 1 D
218,42 USD
0,00% (0,00)
bedtimeEtter stengetid
Stengt: 9. okt., 16:00:01 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for JAZZ …
Åpne
221,79 USD
Høy
227,00 USD
Lav
213,20 USD
Markedsverdi
14,18 mrd.
Snittvolum
935,53k
Volum
1,29 mill.
P/E-forhold
14,93
52 u høy
266,38 USD
52 u lav
128,80 USD
EPS
14,63 USD
Beta
0,37
Utestående aksjer
64,92 mill.
Antall ansatte
3k
Åpne
221,79 USD
Høy
227,00 USD
Lav
213,20 USD
Markedsverdi
14,18 mrd.
Snittvolum
935,53k
Volum
1,29 mill.
P/E-forhold
14,93
52 u høy
266,38 USD
52 u lav
128,80 USD
EPS
14,63 USD
Beta
0,37
Utestående aksjer
64,92 mill.
Antall ansatte
3k
Nyhetssaker
Fra nettkilder og nyhetspartnere
Investing.com Australia
·
for 15 timer siden
Form 144 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY For: 10 October
Traders Union
·
for 1 døgn siden
Jazz Pharmaceuticals gets Cramer backing in CNBC stock call segment
TipRanks
·
for 1 døgn siden
Jazz Pharmaceuticals Plans Commercial Leadership Transition Ahead
ChartMill
·
for 1 døgn siden
Jazz Pharmaceuticals (NASDAQ:JAZZ): An Undervalued Biopharma Value Stock
Profil
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Om Jazz Pharmaceuticals PLC
Administrerende direktørBruce C Cozadd
Ansatte2,89k
Grunnlagt2003
Hovedkontor-
Sektor-
Nettstedjazzpharma.com